Cable Hill Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Cable Hill Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8	Closed	-$4K	–	968
2017 Q4	$4K	Sell	8 -25	-76%	-$8.93K	﹤0.01%	796
2017 Q3	$11K	Buy	+33	New	+$8.99K	0.01%	560
2015 Q2	–	Sell	-1	Closed	-$11K	–	757
2015 Q1	$11K	Hold	1	–	–	0.01%	422
2014 Q4	$13K	Buy	+1	New	+$5.8K	0.01%	388

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cable Hill Partners's EIGR Position: Q1 2018 in Review

Cable Hill Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2018, closing a stake of 8 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in EIGR in Q4 2014 and held it in 4 quarters. The position peaked at $13K in Q4 2014. 39 funds tracked by Wall St. Rank hold EIGR as of Q1 2018.

Cable Hill Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Cable Hill Partners sold 8 Eiger BioPharmaceuticals, Inc. shares in Q1 2018, an estimated $4K.
Cable Hill Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
Cable Hill Partners's Eiger BioPharmaceuticals, Inc. position peaked at $13K in Q4 2014.
39 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.